Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate

Modern Rheumatology

Volumn 25, Issue 2, 2015, Pages 251-256

  Kobayakawa, Tomonori ^a   Kojima, Toshihisa ^a   Takahashi, Nobunori ^a   Hayashi, Masatoshi ^b   Yabe, Yuichiro ^c   Kaneko, Atsushi ^d   Shioura, Tomone ^e   Saito, Kiwamu ^f   Hirano, Yuji ^g   Kanayama, Yasuhide ^h   Miyake, Hiroyuki ⁱ   Asai, Nobuyuki ^a   Funahashi, Koji ^a   Hirabara, Shinya ^g   Hanabayashi, Masahiro ⁱ   Asai, Shuji ^a   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NAGANO RED CROSS HOSPITAL   (Japan)

^c TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e Shizuoka Kosei Hospital   (Japan)

^f Saito Clinic Orthopedic and Rheumatology   (Japan)

^g TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^h Department of Clinical Laboratory   (Japan)

ⁱ Ichinomiya Municipal Hospital   (Japan)

Author keywords

Methotrexate; Rheumatoid arthritis; Second line drug; TNF inhibitor; Tocilizumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; DISEASE DURATION; DIZZINESS; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG PREFERENCE; DRUG RETENTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN CANCER; SKIN ULCER; TUBERCULOSIS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; JAPAN; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924407480     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.953668     Document Type: Article

References (33)

1. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology. 2007; 46(7): 1191–9.
2. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003; 62 Suppl 2: ii30–3.
3. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006; 8(6): R174.
4. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009; 1173: 837–46.
5. Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011; 38(7): 1273–81.
6. Ostergaard M, Unkerskov J, Linde L, Krogh NS, Ravn T, Ringsdal VS, et al. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol. 2007; 36(2): 151–4.
7. Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. A CR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther. 2009; 11(6): R163.
8. Wakabayashi H, Hasegawa M, Nishioka Y, Sudo A, Nishioka K. Which subgroup of rheumatoid arthritis patients benefi ts from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study. Mod Rheumatol. 2012; 22(1): 116–21.
9. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol. 2004; 31(21): 2356–9.
10. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67(11): 1516–23.
11. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69(6): 964–75.
12. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012; 64(5): 625–39.
13. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009; 68(7): 1100–4.
14. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011; 70: 583–9.
15. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low–results from RABBIT, the German biologics register. Arthritis Res Ther. 2006; 8(3): E66.
16. Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol. 2009; 38(1): 11–4.
17. Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Modern Rheumatol. 2014; 24(1): 33–40.
18. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011; 70(7): 1216–22.
19. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al.; CORRONA Investigators. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012; 71(7): 1134–42.
20. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, et al.; TBC. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study. Mod Rheumatol. 2012; 22(3): 339–45.
21. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9): 1580–8.
22. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569–81.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3): 315–24.
24. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009; 19(4): 351–7.
25. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3): 492–509.
26. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(7): 921–6.
27. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54(12): 3782–9.
28. Miyasaka N, Investigators CS. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008; 18(3): 252–62.
29. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and antitumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010; 69(5): 817–21.
30. Scallon B, Cai A, Solowski N, Rosenberg A, Song X, Shealy D, Wagner C. Binding and functional comparisons of two type of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002; 301(2): 418–26.
31. Jamniski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al. The presence or absenc of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011; 70(2): 284–8.
32. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013; 381(9877): 1541–50.
33. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013; 72(1): 43–50.